Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride's impact on fertility is discussed, with users sharing experiences of conceiving while on the medication. Concerns about long-term safety are also mentioned.

Hair regrowth using finasteride 1mg daily and topical minoxidil twice daily, with a hair transplant after three years, showed significant improvement over four years. The user is satisfied with the results despite not having access to oral minoxidil.

The conversation is about considering pyrilutamide 1% as an alternative treatment for hair loss due to intolerance to 5-alpha reductase inhibitors. Some users suggest it might be effective, while others view it as a temporary solution.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

The conversation discusses the sourcing of Pyril by major retailers like Minoxidil Max, RU Direct, and Actifolic. It involves treatments such as Minoxidil, finasteride, and RU58841 for hair loss.

A 20-year-old who started balding in 2020 and has been using a treatment routine for 4 months that includes daily Minoxidil (1.5ml), Finasteride three times a week, and a derma roller twice a week, along with a 2-month course of vitamin supplements. The treatment has significantly improved their hair loss, boosting their confidence.

RU58841 is generally considered ineffective as a standalone hair loss treatment, with most users combining it with finasteride or dutasteride for better results. Few report success using RU58841 alone.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.

The conversation is about comparing the effectiveness of 5% RU58841 and 0.5% pyrilutamide for hair loss treatment. The user is asking if the higher concentration of RU58841 makes it stronger than the lower dose of pyrilutamide.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

A user reported significant hair regrowth after 3 months using 1mg oral finasteride, 1ml 5% topical minoxidil, and microneedling, along with biotin, vitamin D, iron, and zinc supplements. They are optimistic about continued progress despite initial skepticism.

User noticed receding/thinning hairline, used topical finasteride/minoxidil and scalp scrubber for 4 months, saw progress.

A user with low ferritin and zinc levels is asking if others have seen hair improvement after taking iron supplements. They were prescribed minoxidil and finasteride by their doctor.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

The conversation discusses using RU58841 mixed with topical minoxidil for hair loss, noting its chemical instability and storage challenges. A user shares their experience using RU58841 with ethanol and propylene glycol, mentioning no significant results yet.

The user has been using 1mg oral finasteride daily for four years, experiencing significant hair regrowth and increased testosterone levels without negative side effects. They advise patience and monitoring for side effects, noting that their hair continues to improve with this treatment.

A user expressed satisfaction with a hair and beard transplant at HairofIstanbul using 3200 grafts and PRP, achieving natural-looking results without finasteride or minoxidil. The transformation was praised, though some noted the beard line appeared artificial.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

User experienced shortness of breath, high blood pressure, red eyes, and eye floaters after using RU58841 for hair loss. They warn others to avoid RU58841 and stick to finasteride, minoxidil, and dutasteride.

The user is using a hair regrowth treatment plan that includes finasteride, microneedling, minoxidil foam, ketoconazole shampoo, and piroctone olamine shampoo. They are seeking advice on the effectiveness of their regimen and dosage of finasteride, and are curious about others' experiences with piroctone olamine.

The post discusses a new hair loss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

The user shared their 4-month progress using a topical solution of 5% minoxidil and 0.1% finasteride, reporting initial shedding that stopped after 2.5 months and noticeable regrowth, especially in the crown area. They use Glenmark Hair4U F from India and have experienced no side effects.

The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.

Pyrilutamide is discussed as a potential hair loss treatment, acting as an androgen receptor antagonist. The conversation questions if it can maintain hair long-term without using finasteride.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.